Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ervant J. Maksabedian Hernandez, Marlon Graf, Alexandria Portelli & Jason Shafrin. (2022) Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. Journal of Medical Economics 25:1, pages 1118-1126.
Read now
Read now
Kyung-Bok Son. (2022) Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures. Expert Review of Pharmacoeconomics & Outcomes Research 22:5, pages 815-822.
Read now
Read now
Babak Sahragardjoonegani, Reed F. Beall, Aaron S. Kesselheim & Aidan Hollis. (2021) Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. Journal of Pharmaceutical Policy and Practice 14:1.
Read now
Read now
Henry Grabowski, Genia Long, Richard Mortimer & Mehmet Bilginsoy. (2021) Continuing trends in U.S. brand-name and generic drug competition. Journal of Medical Economics 24:1, pages 908-917.
Read now
Read now
Genia Long. (2019) Federal government-interest patent disclosures for recent top-selling drugs. Journal of Medical Economics 22:12, pages 1261-1267.
Read now
Read now
Articles from other publishers (33)
Steven Kozlowski, Natasha Flowers, Andrew Kwist, Sarah K. Dutcher, Michael Wernecke, Jeffrey A. Kelman & David J. Graham. (2022) Uptake and Competition Among Biosimilar Biological Products in the US Medicare Fee-for-Service Population. Journal of General Internal Medicine 37:16, pages 4292-4294.
Crossref
Crossref
Casey B. Mulligan. (2022) Peltzman Revisited: Quantifying 21st-Century Opportunity Costs of Food and Drug Administration Regulation. The Journal of Law and Economics 65:S2, pages S355-S387.
Crossref
Crossref
Kyung-Bok Son & Eui-Kyung Lee. (2022) Importance of a usual source of care in choosing low-priced generic drugs: a cross-sectional study. Family Practice 39:5, pages 791-798.
Crossref
Crossref
Kyung-Bok Son. (2022) Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?. Frontiers in Public Health 10.
Crossref
Crossref
Robin Cantor, Heather Bates & Claire MacKoul. (2021) Risk Attenuation and Amplification in the U.S. Opioid Crisis. Risk Analysis 42:7, pages 1393-1408.
Crossref
Crossref
Ravi Gupta, Christopher J. Morten, Angela Y. Zhu, Reshma Ramachandran, Nilay D. Shah & Joseph S. Ross. (2022) Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021. JAMA Health Forum 3:5, pages e221096.
Crossref
Crossref
Elena A. Bryzgalova-Plan, Marina V. Kovshova, Lidiya B. Larina, Irina O. Ryzhova & Svetlana N. Lobanova. 2022. Сooperation and Sustainable Development. Сooperation and Sustainable Development
1411
1418
.
Jonathan J. Darrow. (2021) The Perils of Increasing Medicaid Rebates for Drugs With Accelerated Approval. JAMA Health Forum 2:10, pages e213184.
Crossref
Crossref
Sunand Kannappan, Jonathan J. Darrow, Aaron S. Kesselheim & Reed F. Beall. (2021) The timing of 30‐month stay expirations and generic entry: A cohort study of first generics, 2013–2020. Clinical and Translational Science 14:5, pages 1917-1923.
Crossref
Crossref
Louis P GarrisonJrJrBoshen JiaoOmar Dabbous. (2021) Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies. Journal of Managed Care & Specialty Pharmacy 27:5, pages 674-681.
Crossref
Crossref
Victoria Serra-Sastre, Simona Bianchi, Jorge Mestre-Ferrandiz & Phill O’Neill. (2020) Does NICE influence the adoption and uptake of generics in the UK?. The European Journal of Health Economics 22:2, pages 229-242.
Crossref
Crossref
Jonathan J. DarrowDonald W. Light. (2021) Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding. Health Affairs 40:2, pages 281-288.
Crossref
Crossref
Reed F. Beall, Paul E. Ronksley, James Wick, Jonathan J. Darrow, Ameet Sarpatwari & Aaron S. Kesselheim. (2020) Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clinical Pharmacology & Therapeutics 108:6, pages 1308-1314.
Crossref
Crossref
Saranrat Wittayanukorn, Matthew Rosenberg, Andreas Schick, Meng Hu, Zhong Wang, Andrew Babiskin, Robert Lionberger & Liang Zhao. (2020) Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions. Therapeutic Innovation & Regulatory Science 54:6, pages 1372-1381.
Crossref
Crossref
David Cutler, Noam Kirson & Genia Long. (2020) Financing Drug Innovation in the US: Current Framework and Emerging Challenges. PharmacoEconomics 38:9, pages 905-911.
Crossref
Crossref
Wei Zhang, Daphne P. Guh, Huiying Sun, Larry D. Lynd, Aidan Hollis, Paul Grootendorst & Aslam H. Anis. (2020) Factors associated with drug shortages in Canada: a retrospective cohort study. CMAJ Open 8:3, pages E535-E544.
Crossref
Crossref
Dhruv Khullar, Jennifer A. OhnMark TrusheimPeter B. Bach. (2020) Understanding the Rewards of Successful Drug Development — Thinking Inside the Box. New England Journal of Medicine 382:5, pages 473-480.
Crossref
Crossref
Jonathan J. Darrow, Jerry Avorn & Aaron S. Kesselheim. (2020) FDA Approval and Regulation of Pharmaceuticals, 1983-2018. JAMA 323:2, pages 164.
Crossref
Crossref
Reed F. Beall, Amity E. Quinn, Aaron S. Kesselheim, Frazer A. Tessema & Ameet Sarpatwari. (2021) Generic Competition for Drugs Treating Rare Diseases. The Journal of Law, Medicine & Ethics 48:4, pages 789-795.
Crossref
Crossref
Yucheng Ding & Xin Zhao. (2019) Pay-for-delay patent settlement, generic entry and welfare. International Journal of Industrial Organization 67, pages 102532.
Crossref
Crossref
Reed F. Beall, Lorian Hardcastle, Fiona Clement & Aidan Hollis. (2019) How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?. Health Policy 123:12, pages 1251-1258.
Crossref
Crossref
Meng Hu, Andrew Babiskin, Saranrat Wittayanukorn, Andreas Schick, Matthew Rosenberg, Xiajing Gong, Myong‐Jin Kim, Lei Zhang, Robert Lionberger & Liang Zhao. (2019) Predictive Analysis of First Abbreviated New Drug Application Submission for New Chemical Entities Based on Machine Learning Methodology. Clinical Pharmacology & Therapeutics 106:1, pages 174-181.
Crossref
Crossref
Kyung-Bok Son, SeungJin Bae & Tae-Jin Lee. (2019) Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-U.S. Free Trade Agreement in Korea. International Journal of Health Services 49:2, pages 306-321.
Crossref
Crossref
Reed F. BeallAaron S. KesselheimAmeet Sarpatwari. (2019) New Drug Formulations and Their Respective Generic Entry Dates. Journal of Managed Care & Specialty Pharmacy 25:2, pages 218-224.
Crossref
Crossref
Jonathan J. Darrow, Reed F. Beall & Aaron S. Kesselheim. (2018) The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Applied Health Economics and Health Policy 17:1, pages 47-54.
Crossref
Crossref
Reed F. Beall, Jonathan J. Darrow & Aaron S. Kesselheim. (2019) Patent term restoration for top-selling drugs in the United States. Drug Discovery Today 24:1, pages 20-25.
Crossref
Crossref
Kyung-Bok Son. (2018) Establishing healthy pharmaceutical regulations on statutory exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 14:4, pages 167-174.
Crossref
Crossref
Reed F. Beall, Jonathan J. Darrow & Aaron S. Kesselheim. (2018) A Method for Approximating Future Entry of Generic Drugs. Value in Health 21:12, pages 1382-1389.
Crossref
Crossref
Michael S. Sinha, Mehdi Najafzadeh, Elizabeth K. Rajasingh, James Love & Aaron S. Kesselheim. (2018) Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012. JAMA Internal Medicine 178:11, pages 1458.
Crossref
Crossref
Gerard T. Vondeling, Qi Cao, Maarten J. Postma & Mark H. Rozenbaum. (2018) The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review. Applied Health Economics and Health Policy 16:5, pages 653-660.
Crossref
Crossref
Qian Liu, Abigail R. Smith, Jeong M. Park, Murewa Oguntimein, Sarah Dutcher, Ghalib Bello, Margaret Helmuth, Marc Turenne, Rajesh Balkrishnan, Melissa Fava, Charlotte A. Beil, Adam Saulles, Sangeeta Goel, Pratima Sharma, Alan Leichtman & Jarcy Zee. (2018) The adoption of generic immunosuppressant medications in kidney, liver, and heart transplantation among recipients in Colorado or nationally with Medicare part D. American Journal of Transplantation 18:7, pages 1764-1773.
Crossref
Crossref
Jonathan J Darrow, Reed F Beall & Aaron S Kesselheim. (2017) Will inter partes review speed US generic drug entry?. Nature Biotechnology 35:12, pages 1139-1141.
Crossref
Crossref
Casey B. Mulligan. (2021) Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation. SSRN Electronic Journal.
Crossref
Crossref